Ask AI
Matthew Gubens

Matthew Gubens, MD, MS, FASCO

Medical Director, Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California

Explore Activities by Matthew Gubens

Title
Format
Credit Type
Credits
HER2 in Context in NSCLC, Testing Strategies and Advances in Methodologies, and a Brief Review of ADCs in NSCLC

Content Format:

Slideset

Credit Type:

--

Credits:

--
Evolving Role of HER2-Directed Antibody–Drug Conjugates in the Management of Patients With Advanced NSCLC

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Clinical Integration of ADCs Into Treatment Plans for Patients With NSCLC: Answers to Your Questions

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Novel Combinatorial Approaches With TROP-2–Targeted Therapy in Advanced NSCLC

Content Format:

Text Module

Credit Type:

AMA

Credits:

0.25
Novel Combinatorial Approaches With TROP-2–Targeted Therapy in Advanced NSCLC

Content Format:

Slideset

Credit Type:

--

Credits:

--
Identification and Management of Adverse Events With TROP-2–Targeted ADCs

Content Format:

Slideset

Credit Type:

--

Credits:

--
Identification and Management of AEs With TROP-2–Targeted ADCs

Content Format:

Text Module

Credit Type:

AMA

Credits:

0.25
2023 World Conference on Lung Cancer: Expert Perspectives on Key Studies

Content Format:

Text Module

Credit Type:

AAPA | ACPE | AMA | ANCC

Credits:

1.50
Assessing Adverse Events in Patients Receiving Chemoimmunotherapy Regimens for Non-Small-Cell Lung Cancer

Content Format:

Tool

Credit Type:

--

Credits:

--
2023 World Conference on Lung Cancer Preview: Experts Choose the Top Abstracts

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--